Training Program in Cancer Therapeutics

癌症治疗培训计划

基本信息

  • 批准号:
    7280437
  • 负责人:
  • 金额:
    $ 39.17万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-09-01 至 2011-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): To improve cancer therapy, it is increasingly critical that advances in basic cancer research be translated to the clinic. In the Training Program in Cancer Therapeutics, the goal is to provide training to cancer researchers in the action of therapeutic agents used in the treatment of cancer. This Training Program will be multi-disciplinary and expose the trainees to both basic research involving cancer therapeutic agents and the clinical utilization of therapeutics. A particular emphasis will be placed on the mechanisms through which basic scientific discovery is brought into the clinic through clinical trials. To facilitate this training, a team of mentoring faculty and ancillary clinical faculty has been recruited into the Training Program from the University of Cincinnati and Cincinnati Children's Hospital Medical Center. All mentors on this training program are independently funded, have experience in mentoring, and work on projects related to cancer therapy. The ancillary faculty are clinical partners on this proposal, who will educate on the clinical utilization of specific therapeutic modalities. Together, the mentors and ancillary faculty will provide training both through direct interactions and through specialized educational activities and course work for the Training Program. This Program will provide outstanding career development for trainees, as more emphasis is placed on translating basic scientific discovery into improved patient care. Logistically, the Training Program in Cancer Therapeutics has 19 mentors and 6 ancillary faculty. It is administered by the Principal Investigator and Administrative Committees, which are directed at training excellence and providing an ethnically and scientifically diverse group of trainees. The Training Program requests support for 6 postdoctoral and 2 predoctoral trainees. The program will be evaluated regularly through both internal and external review to ensure that the trainees are receiving the best possible training.
描述(由申请人提供):为了改进癌症治疗,将基础癌症研究的进展转化为临床越来越重要。在癌症治疗培训计划中,目标是为癌症研究人员提供治疗药物在癌症治疗中的作用方面的培训。这一培训计划将是多学科的,让受训者接触到涉及癌症治疗药物的基础研究和治疗学的临床应用。将特别强调通过临床试验将基本科学发现带入临床的机制。为了促进这一培训,从辛辛那提大学和辛辛那提儿童医院医学中心招募了一支由指导教师和辅助临床教师组成的团队参加培训计划。该培训计划中的所有导师都是独立资助的,都有指导经验,并参与了与癌症治疗相关的项目。辅助教员是这项提案的临床合作伙伴,他们将就特定治疗方式的临床应用进行教育。导师和辅助教员将通过直接互动以及通过专门的教育活动和培训计划的课程工作共同提供培训。该计划将为实习生提供出色的职业发展,因为更多的重点是将基本的科学发现转化为更好的患者护理。 在后勤方面,癌症治疗培训计划有19名导师和6名辅助教员。它由首席调查员和行政委员会管理,旨在培训优秀人才,并提供不同种族和不同科学背景的受训人员。培训方案要求为6名博士后和2名博士后学员提供支持。该计划将通过内部和外部审查定期进行评估,以确保受训人员接受尽可能好的培训。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

PETER J. STAMBROOK其他文献

PETER J. STAMBROOK的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('PETER J. STAMBROOK', 18)}}的其他基金

Pathways to Mutagenesis in vivo and in Stem Cells
体内和干细胞的诱变途径
  • 批准号:
    7916980
  • 财政年份:
    2009
  • 资助金额:
    $ 39.17万
  • 项目类别:
Environmental exposure: Susceptibility alleles in a DNA damage response pathway
环境暴露:DNA 损伤反应途径中的易感性等位基因
  • 批准号:
    8215811
  • 财政年份:
    2008
  • 资助金额:
    $ 39.17万
  • 项目类别:
Environmental exposure: Susceptibility alleles in a DNA damage response pathway
环境暴露:DNA 损伤反应途径中的易感性等位基因
  • 批准号:
    8391760
  • 财政年份:
    2008
  • 资助金额:
    $ 39.17万
  • 项目类别:
Environmental exposure: Susceptibility alleles in a DNA damage response pathway
环境暴露:DNA 损伤反应途径中的易感性等位基因
  • 批准号:
    7575486
  • 财政年份:
    2008
  • 资助金额:
    $ 39.17万
  • 项目类别:
Environmental exposure: Susceptibility alleles in a DNA damage response pathway
环境暴露:DNA 损伤反应途径中的易感性等位基因
  • 批准号:
    8020143
  • 财政年份:
    2008
  • 资助金额:
    $ 39.17万
  • 项目类别:
Environmental Mutagen Society 38th Annual Meeting
环境诱变剂学会第38届年会
  • 批准号:
    7404979
  • 财政年份:
    2007
  • 资助金额:
    $ 39.17万
  • 项目类别:
Pathways to Mutagenesis in vivo and in Stem Cells
体内和干细胞的诱变途径
  • 批准号:
    7148780
  • 财政年份:
    2006
  • 资助金额:
    $ 39.17万
  • 项目类别:
Pathways to Mutagenesis in vivo and in Stem Cells
体内和干细胞的诱变途径
  • 批准号:
    7644010
  • 财政年份:
    2006
  • 资助金额:
    $ 39.17万
  • 项目类别:
Pathways to Mutagenesis in vivo and in Stem Cells
体内和干细胞的诱变途径
  • 批准号:
    7274874
  • 财政年份:
    2006
  • 资助金额:
    $ 39.17万
  • 项目类别:
Pathways to Mutagenesis in vivo and in Stem Cells
体内和干细胞的诱变途径
  • 批准号:
    7454254
  • 财政年份:
    2006
  • 资助金额:
    $ 39.17万
  • 项目类别:

相似海外基金

Investigation of crosstalk between Fanconi Anemia pathway and ATM for novel therapeutic strategies of chemoresistant ALT-positive high-risk neuroblastoma
范可尼贫血通路与 ATM 之间的串扰研究,用于化疗耐药 ALT 阳性高危神经母细胞瘤的新治疗策略
  • 批准号:
    24K10442
  • 财政年份:
    2024
  • 资助金额:
    $ 39.17万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Intelligent Breast Cancer DiagnOsis and MonItoring Therapeutic Response Training Network (CanDoIt)
智能乳腺癌诊断和监测治疗反应训练网络(CanDoIt)
  • 批准号:
    EP/Y03693X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.17万
  • 项目类别:
    Research Grant
Non invasive methods to accelerate the development of injectable therapeutic depots
非侵入性方法加速注射治疗储库的开发
  • 批准号:
    EP/Z532976/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.17万
  • 项目类别:
    Research Grant
GPR35: mechanisms of action and agonism as a potential therapeutic strategy for non-alcoholic fatty liver diseases
GPR35:作为非酒精性脂肪肝疾病潜在治疗策略的作用和激动机制
  • 批准号:
    MR/X008827/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.17万
  • 项目类别:
    Research Grant
Collaborative Research: CPS: Medium: Automating Complex Therapeutic Loops with Conflicts in Medical Cyber-Physical Systems
合作研究:CPS:中:自动化医疗网络物理系统中存在冲突的复杂治疗循环
  • 批准号:
    2322534
  • 财政年份:
    2024
  • 资助金额:
    $ 39.17万
  • 项目类别:
    Standard Grant
Uncovering the antimicrobial and antibiotic potentiating mechanism of acesulfame-K and maximising its topical therapeutic potential.
揭示安赛蜜的抗菌和抗生素增强机制并最大限度地发挥其局部治疗潜力。
  • 批准号:
    MR/Y001354/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.17万
  • 项目类别:
    Research Grant
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 39.17万
  • 项目类别:
    Collaborative R&D
Preclinical validation of synthetic biomolecules to treat Breast Cancer from AI-enabled discovery of novel lncRNA therapeutic targets.
通过人工智能发现新型 lncRNA 治疗靶点,对合成生物分子治疗乳腺癌进行临床前验证。
  • 批准号:
    10110204
  • 财政年份:
    2024
  • 资助金额:
    $ 39.17万
  • 项目类别:
    Launchpad
Analysis and quality control of novel mixed cell population for therapeutic development
用于治疗开发的新型混合细胞群的分析和质量控制
  • 批准号:
    10089851
  • 财政年份:
    2024
  • 资助金额:
    $ 39.17万
  • 项目类别:
    Collaborative R&D
Using patient-led genetics to identify new therapeutic targets in metastatic cholangiocarcinoma
利用患者主导的遗传学来确定转移性胆管癌的新治疗靶点
  • 批准号:
    EP/Y028546/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.17万
  • 项目类别:
    Fellowship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了